Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24742301 | 1.00 | HDAC6 (0.36) | HDAC6RPS6KB1CHRM1SLC6A2SLC6A4 | |
| SCHEMBL30069706 | 1.00 | HDAC6 (0.36) | HDAC6RPS6KB1CHRM1SLC6A2SLC6A4 | |
| SCHEMBL16322078 | 0.85 | GAA (0.38) | ALDH1A1 | |
| SCHEMBL15922771 | 0.85 | GAA (0.38) | ALDH1A1 | |
| SCHEMBL16322079 | 0.85 | GAA (0.38) | ALDH1A1 | |
| SCHEMBL29157522 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL29157519 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL14809562 | 0.82 | MAPK1 (0.36) | ALDH1A1 | |
| SCHEMBL14809014 | 0.82 | MAPK1 (0.36) | ALDH1A1 | |
| SCHEMBL14809561 | 0.82 | MAPK1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294500-A1 | ISOINDOLINONE COMPOUNDS, AND USES THEREOF | HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4352046-A1 | ISOINDOLINONE COMPOUNDS, AND USES THEREOF | Hangzhou Glubio Pharmaceutical Co., Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022257897-A1 | ISOINDOLINONE COMPOUNDS, AND USES THEREOF | HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD. (CN) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294500-A1 | ISOINDOLINONE COMPOUNDS, AND USES THEREOF | PKD1, SLC10A1, TP53 | HDAC6 128/4885RPS6KB1 2493/4885CHRM1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.